BioCentury | Sep 14, 2019
Product Development

Success in lung cancer niches will hinge on access to next-gen sequencing

...Fisher Scientific Inc. to develop companion diagnostics. Illumina is developing the NGS-based pan-cancer companion diagnostic TruSight Tumor 170...
BioCentury | Mar 15, 2018
Tools & Techniques

Shared burden

...with Foundation’s 324-gene panel (R 2 = 0.95), according to Fabrizio, and with Illumina Inc.’s TruSight Tumor 170...
...profiling mutations in cell-free DNA in plasma using a 394-gene panel Illumina Inc. (NASDAQ:ILMN) (A) TruSight Tumor 170...
BioCentury | Jan 13, 2017
Company News

Illumina, IBM deal

...Watson for Genomics to compare variant genetic data produced by TruSight Tumor 170 to published medical literature. TruSight Tumor 170...
BioCentury | Jan 11, 2017
Company News

Illumina rises after introducing new products, deals

...to standardize and simplify genomic data interpretation. Illumina will pair its cancer genome sequencing panel, TruSight Tumor 170...
BioCentury | Nov 17, 2016
Company News

Illumina sales and marketing update

...Illumina launched TruSight Tumor 170 next-generation sequencing solution to evaluate tumor biomarkers. The research use only test runs...
Items per page:
1 - 5 of 5